Skip to content
drillr.ai

UPB

Upstream Bio, Inc.

NASDAQ · USHealthcareBiotechnology
$6.98-0.43%

Price as of Jul 20, 2026

UPB news

Upstream Bio, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

    – Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with and without comorbid asthma, as well as rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers – WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (https://w

    Globe Newswire ·

  2. Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

    – Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (https://www.globenewswire.com/Tracker?data=-AdS9yxTNfl7CkcYF1Xj7uHeSYVJ9T2NbWrTh5sYkdbYaJ8hs48r3fO-jLGyRWkRDXAiPWy

    Globe Newswire ·

  3. Upstream Bio to Participate in Upcoming March Investor Conferences

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNX59fmxv&default-theme=true WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (https://www.globenewswire.com/Tracker?data=e2BcStbpwxS5l0wxJJ0d1v2PVC5a9wZ2gpVqqMw00Gbb8bdSJauHUawyIxmFfNIRBtGbJM4tu9aCvhEZxtHZA0PJkfrSprdixS0tnVJMqMY=) (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory d

    Globe Newswire ·